Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
GSK has reached a major milestone with the NMPA’s Exdensur depemokimab China approval. This ultra-long-acting biologic offers a breakthrough for severe asthma patients, requiring only two doses per year to maintain symptom control.
TECNIS PureSee IOL clinical data took center stage at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, as Johnson & Johnson [Read More…]
Gilead Sciences has entered into a definitive agreement to acquire Tubulis for up to $5 billion, adding the “best-in-class” TUB-040 asset and a next-generation ADC platform to its growing oncology portfolio.
Amgen has announced successful topline results from its Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA® for Thyroid Eye Disease, offering a new, convenient delivery method.
Thermo Fisher Scientific has unveiled the Gibco CHOvantage GS, a next-generation biologics development platform designed to accelerate timelines to the clinic while ensuring regulatory compliance and scalability.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
